EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Sun Exposure Lowers Risk of Breast Cancer, Study Finds January 6, 2022 Lack of Evidence for the Use of Telemedicine in the Prevention... September 13, 2021 ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... April 27, 2021 Load more HOT NEWS Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma Experimental Cancer Drug Metarrestin Targets Metastatic Tumors
